The St. Petersburg Research Institute of Vaccines and Serums, part of the Federal Medical and Biological Agency (FMBA), has obtained approval to conduct Phase II and III clinical trials of a pentavalent meningococcal vaccine. The information was published in the State Register of Medicines.
The primary objective of these trials is to demonstrate that the MCV-5 vaccine elicits an immune response comparable to the Menactra vaccine, produced by Sanofi, against serotypes A, C, W, and Y, while providing superior efficacy against serotype B.
The vaccine is formulated as a suspension for intramuscular injection, with a dosage of 0.5 ml per dose. The trials will be carried out across 16 medical organizations.
In July, FMBA officials indicated that the meningococcal vaccine could be available for use in 2027. Discussions are also ongoing regarding the inclusion of this vaccine in Russia’s National Vaccination Calendar. Meanwhile, the spread of meningitis in Russia is outpacing updates to the vaccination schedule, as reported by GxP News.
